Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Substance P peptide icon, one bubble per amino acidSubstance P11 residuesRPKPQQFFGLMEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Substance P

ImmuneResearch
~1-2 minutes half-life·Injection·4w on / 4w off

Also known as: SP, Tachykinin Precursor 1 fragment, Neurokinin 1 ligand

Over 20,000 PubMed citations since 1931, yet zero human clinical trials for wound healing. Substance P is an endogenous 11-amino-acid neuropeptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) of the tachykinin family that signals through the neurokinin-1 receptor (NK1R). Its tissue half-life sits around 1 to 2 minutes. Neutral endopeptidase (NEP) chews through it almost immediately after release. Preclinical models show Substance P mobilizes bone marrow stem cells, accelerates wound closure, and drives angiogenesis. But the pharmacokinetics make subcutaneous self-administration largely impractical for systemic benefit. This is a laboratory research molecule, not a consumer peptide.

What Is Substance P?

Eleven amino acids. One of the oldest known neuropeptides in biomedical science. Substance P (SP, also tachykinin precursor 1 fragment; CAS 33507-63-0) was first isolated from horse brain and intestine by Ulf von Euler and John Gaddum in 1931, making it one of the first neuropeptides ever described.

SP binds the neurokinin-1 receptor (NK1R) on neurons, immune cells, keratinocytes, and endothelial cells. That single receptor mediates a paradox: the same signaling that amplifies pain also kicks off wound repair. Kim and colleagues confirmed this in a 2009 Nature Medicine study [1], showing that IV Substance P mobilized CD29+/CD45-/CD11b- stromal-like cells from bone marrow in mice, rats, and rabbits. Khalifa's group extended the picture in 2024 [2], demonstrating that SP restores asymmetric stem cell divisions in denervated skin wounds.

The clinical reality is more complicated. NEP (neutral endopeptidase, also called CD10) degrades SP in tissue within 1 to 2 minutes. Subcutaneous bioavailability registers as "very low" because local enzymatic destruction outpaces systemic distribution. No self-administration community exists. It isn't sold as a consumer peptide. Research-grade SP runs $50 to $150 per milligram, sold only as a lab reagent. The most pharmacologically rational application, topical SP-fragment eye drops for corneal healing, has the closest thing to human evidence, but even that sits at case-series level.

How Substance P Works

Substance P binds with high affinity to the neurokinin-1 receptor (NK1R), a Gq/11-coupled GPCR expressed across neurons, immune cells, keratinocytes, and vascular endothelium. Receptor activation triggers phospholipase C, releasing inositol trisphosphate (IP3) and diacylglycerol (DAG). Intracellular calcium spikes. Protein kinase C (PKC) activates.

In nociceptive C-fibers, that cascade amplifies pain signals transmitted from peripheral nerve terminals to the spinal dorsal horn. SP co-localizes with CGRP in sensory neurons; the two peptides are often released together during neurogenic inflammation.

The immune arm of NK1R signaling is equally aggressive. Mast cells degranulate, dumping histamine and proteases. Macrophages and neutrophils get recruited via chemotaxis. T-cells proliferate. Cytokine output increases across IL-1, IL-6, and TNF-alpha. That inflammatory burst, while uncomfortable in the short term, is the opening phase of wound healing.

The repair arm follows. SP stimulates fibroblast proliferation and collagen synthesis at the wound site. It upregulates vascular endothelial growth factor (VEGF), driving angiogenesis. The bone marrow mobilization pathway (Kim 2009)[1] recruits CD29+ stromal-like cells from marrow to peripheral injury sites. Khalifa's 2024 data [2] added that SP specifically restores asymmetric stem cell division in denervated tissue, a mechanism lost when sensory innervation is damaged.

Substance P Benefits

  • Substance P benefits center on wound healing, immune activation, and stem cell mobilization.
  • Mobilizes CD29+/CD45-/CD11b- bone marrow stromal-like cells to peripheral injury sites via NK1R signaling (Kim et al., Nature Medicine 2009, confirmed across mice, rats, and rabbits)[1].
  • Restores asymmetric stem cell divisions in denervated skin wounds, a finding from Khalifa's 2024 work in Stem Cells [2] that could explain impaired healing in diabetic neuropathy.
  • Stimulates fibroblast proliferation and collagen deposition at wound sites through direct NK1R activation on dermal fibroblasts.
  • Drives angiogenesis via VEGF upregulation, supporting new blood vessel formation in ischemic or wounded tissue.
  • SP-fragment (FGLM-amide) combined with IGF-1 as topical eye drops accelerated corneal re-epithelialization in Japanese case series of neurotrophic keratopathy, the most clinically advanced SP application.
  • Activates macrophage phenotype switching; a 2015 American Journal of Pathology study [3] confirmed SP improved wound healing in diabetic mouse models by modulating inflammation and macrophage polarization.

Substance P: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 8 key studies·Research only

Preclinical data (animal models, in vitro) consistently supports NK1R-mediated wound healing, bone marrow stem cell mobilization, and corneal epithelial repair.

Dosing studied: Animal studies: 5–250 nmol/kg IV/SC. Human research extrapolation: 50–200 mcg SC (near wound site, speculative, no published validation). Corneal: 1 mM solution topical drops.
Read the evidence (key study, limitations)

Zero human clinical trials exist for systemic wound healing use. SC route likely pharmacologically ineffective for systemic benefit due to ~1-2 min tissue half-life and very low SC bioavailability.

Key Study

Kim et al. 2009, Nature Medicine (PMID 19270709): IV SP mobilizes CD29+/CD45−/CD11b− stromal-like cells from bone marrow in mice, rats, and rabbits; Khalifa et al. 2024, Stem Cells (PMID 38301639): SP restores asymmetric stem cell divisions in denervated skin wounds (2024)

Limitations

All wound healing data is preclinical. No human RCTs for systemic SP wound healing. SC bioavailability is very low: rapid NEP-mediated extracellular degradation. Simultaneous pro-nociceptive and pro-inflammatory effects complicate therapeutic use. Circulating substance P clears fast too, with a plasma half-life of 1.6 minutes during IV infusion in 6 healthy subjects (PMID 2425412).

Community Experience
Weak
3.5/5
Based on none: zero self-administration reports found across r/peptides, r/steroids, Longecity, or general biohacking communities as of April 2026

No self-administration community exists.

Community dosing: None documented: no community dosing data exists
Read the reports (common issues 4)

Substance P is not discussed or used in biohacker, peptide, or sports medicine communities. It is a laboratory research reagent with no consumer peptide market presence.

What users report (0)
    Common issues (4)
    • No community self-administration data exists: zero Reddit threads, Longecity posts, or forum protocols found
    • Not sold as a mainstream consumer peptide
    • Pro-nociceptive effects (pain amplification at injection site) would likely discourage recreational use
    • Cost ($50–150/mg research grade) and institutional sourcing requirements limit access
    Science-Only Evidence

    Substance P has no self-administration community. All available data is from preclinical research (animal models, in vitro studies). There is no community experience to align or diverge from the scientific literature. This is a laboratory research molecule only.

    Substance P Dosage Guide

    SpeculativeNo human therapeutic dosing exists. Published human exposure is intradermal challenge testing at 5 to 150 pmol, about 0.007 to 0.2 mcg (PMID 37547990). The tiers here are not established by any source, and every citation on this page is animal or review work.Source (opens in a new tab)
    LevelDose / InjectionFrequency
    Beginner50 mcgNo source establishes this dose. The largest published human exposure is 150 pmol given intradermally, about 0.2 mcg, as a challenge test to raise a wheal (PMID 37547990). This tier is roughly 250 times that amount.Single dose (local injection near wound site)
    Moderate100 mcgNo source establishes this dose. The largest published human exposure is 150 pmol given intradermally, about 0.2 mcg, as a challenge test to raise a wheal (PMID 37547990). This tier is roughly 500 times that amount.Single dose (local injection near wound site)
    Aggressive200 mcgNo source establishes this dose. The largest published human exposure is 150 pmol given intradermally, about 0.2 mcg, as a challenge test to raise a wheal (PMID 37547990). This tier is roughly 990 times that amount.Single dose (local injection near wound site)
    Note:

    Start with two practical realities. First: Substance P is not sold as a consumer peptide. It is sold only as a lab reagent for research, usually to institutional accounts. Second: the 1 to 2 minute tissue half-life means distant subcutaneous injection (abdomen for a knee wound, for example) is pharmacologically pointless. Inject directly at or immediately adjacent to the target tissue.

    Reconstitution math for a 2 mg vial: add 2 mL bacteriostatic water. Concentration equals 1 mg/mL, or 1 mcg per uL. A 50 mcg dose equals 50 uL, which is 5 units on a U-100 insulin syringe. A 100 mcg dose equals 10 units. A 200 mcg dose equals 20 units.

    For a 5 mg vial with 2 mL BAC water: concentration is 2.5 mg/mL, or 2.5 mcg per uL. A 50 mcg dose equals 20 uL (2 units). A 100 mcg dose equals 40 uL (4 units).

    Aliquot into single-use volumes immediately after reconstitution. SP is sensitive to oxidation and protease contamination. Do not store reconstituted solution beyond 7 days at 2 to 8 degrees Celsius. Avoid freeze-thaw cycles entirely.

    Cycling Protocol

    On Period
    4 weeks
    Off Period
    4 weeks

    Due to its pro-inflammatory nature, extended continuous use is not recommended. Short research cycles with equal off-periods are standard practice. Monitor inflammatory markers.

    Calculate your Substance P dose
    Free dosage calculator with syringe visualization

    Or use the universal Peptide Calculator for any peptide.

    Substance P Protocols by Goal

    advancedClinical TrialMaximum 4 weeks; follow with equal off period due to pro-inflammatory risk
    Local injection near wound site
    Wk 1–4
    50–100 mcg · Daily · Subcutaneous (near wound site)

    Expected: Preclinical: accelerated wound closure, increased fibroblast/keratinocyte proliferation, angiogenesis markers at wound site. No human evidence. Systemic effects from SC are unlikely given rapid NEP-mediated local degradation.

    Monitor: Monitor for neurogenic inflammation (erythema, edema, pain amplification) at injection site. Check CRP/ESR at week 2 if continuing. Contraindicated in asthma: monitor spirometry if respiratory history.

    How to Use Substance P

    1. 1
      Step 1

      Verify the certificate of analysis shows at least 95% HPLC purity and correct molecular weight (1,347.63 Da). Research-grade only.

    2. 2
      Reconstitute

      Add 2 mL bacteriostatic water to a 2 mg vial. Swirl gently. Do not shake or vortex. Final concentration: 1 mcg per uL.

    3. 3
      Draw your dose

      For a 50 mcg beginner dose, draw to the 5-unit mark on a U-100 insulin syringe. For 100 mcg (moderate), draw to 10 units. For 200 mcg (aggressive), draw to 20 units.

    4. 4
      Step 4

      Inject subcutaneously at or immediately adjacent to the target wound or tissue site. Use a 29 to 31 gauge, 1/2 inch insulin needle. Clean the site with alcohol first.

    5. 5
      Expect immediate local effects

      Erythema, warmth, and pain amplification at the injection site are normal NK1R pharmacology. These should resolve within hours.

    6. 6
      Step 6

      Store the remaining reconstituted vial at 2 to 8 degrees Celsius. Use within 7 days. Aliquoting into single-use volumes at reconstitution time is strongly recommended.

    7. 7
      Monitor

      Track wound site with dated photographs. Check CRP/ESR at week 2 if continuing past the first week. Stop if erythema persists beyond 24 hours, pain becomes disproportionate, or any respiratory symptoms develop.

    Alternative Routes

    Intravenous (IV) infusion

    5–250 nmol/kg continuous infusion (animal studies); 10 nM/kg single IV dose for stem cell mobilization (Kim 2009). Continuous infusion required due to 1-2 min tissue half-life.

    IV is the only route achieving meaningful systemic exposure in published research. Used in the landmark Kim 2009 Nature Medicine CD29+ stem cell mobilization study. Requires clinical research setting with hemodynamic monitoring. Not a self-administration option. Potent vasodilation at higher doses: hypotension risk.

    Topical (ophthalmic drops)

    1 mM solution, 5 µL per drop, 4–6x daily; bypasses systemic enzymatic degradation by acting locally at corneal surface

    SP-fragment (FGLM-amide) + IGF-1 combination drops used in Japanese ophthalmology case series for persistent corneal epithelial defects. 2024 AJP Cell Physiology study (Sugioka) confirms SP potentiates TGF-β-driven corneal collagen synthesis via NK1R/p38 MAPK. Biomolecules 2025 review (PMC12109903) covers dual pro-repair/pro-inflammatory SP role in cornea. Most pharmacologically rational SP application given the half-life constraints.

    Subcutaneous (SC)

    50–200 mcg near wound site (speculative; no validated human dose: see FLAG P0)

    SC bioavailability is "very low" per site pkData. Injection directly at wound site maximizes local exposure before enzymatic degradation. Systemic benefit from distant SC injection is pharmacologically unsupported. All community dosing values (50/100/200 mcg) are unsourced extrapolations.

    Mixing your own vial? Use the Substance P reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Substance P Stacking Protocols

    Works With

    Avoid

    NK1 receptor antagonists (aprepitant, fosaprepitant, netupitant, tradipitant)

    Directly block NK1R: will completely negate all SP effects. Pharmacological opposites. Note: tradipitant was FDA-approved December 2025 for motion sickness.

    Do not combine
    ACE inhibitors (lisinopril, enalapril, ramipril, perindopril)

    ACE is a primary SP degradation enzyme. ACE inhibition prolongs and potentiates SP activity unpredictably, intensifying both pro-inflammatory and pro-nociceptive effects. Also contributes to ACEi-associated dry cough mechanism (alongside bradykinin).

    NEP inhibitors / sacubitril (Entresto component)

    Neutral endopeptidase (NEP/neprilysin) is the primary tissue-degradation enzyme for SP. NEP inhibition (as in sacubitril, part of sacubitril/valsartan) could markedly prolong SP tissue exposure and amplify neurogenic inflammation.

    Estimated Cost

    Substance P Side Effects

    NK1R activation is inherently pro-inflammatory and pro-nociceptive. Pain amplification at the injection site is expected pharmacology, not a side effect to push past. SP stimulates C-fiber nociceptors and sensitizes dorsal horn neurons. If you inject near a wound, local pain will increase before any healing benefit appears.

    Mast cell degranulation occurs within minutes. Histamine release causes vasodilation, edema, and erythema at the injection site. In most subjects this resolves within hours as NEP degrades the peptide. Persistent erythema or edema beyond 24 hours signals that tissue inflammatory load has exceeded the acute phase, and dosing should stop.

    Bronchoconstriction in susceptible individuals is the most dangerous acute risk. NK1R sits on airway smooth muscle. SP-mediated bronchoconstriction in anyone with asthma, COPD, or reactive airway disease could trigger a medical emergency. Spirometry screening before any use is mandatory. Any wheezing, chest tightness, or respiratory discomfort after injection means immediate discontinuation with no rechallenge.

    Nausea and flushing have been reported across SP infusion studies. These reflect systemic vasodilatory and emetic pathway activation through NK1R in the brainstem area postrema, the same receptor targeted by aprepitant (Emend) for chemotherapy-induced nausea.

    Neuropsychiatric exacerbation is a real concern. Substance P levels are raised in major depression, anxiety disorders, and PTSD (O'Connor et al., J Cell Physiol 2004)[4]. Exogenous administration could worsen these conditions. Screen for active psychiatric symptoms before any research use.

    Published human data on exogenous SP administration is extremely thin. Corneal SP-fragment eye drops represent the most tested human route, and even those are case-series level. Systemic IV infusion studies have included fewer than 50 total subjects across all publications. There is no long-term safety data for any route.

    Pregnancy and breastfeeding: no safety data exists. Absolute contraindication.

    Active malignancy: SP and NK1R signaling have been implicated in tumor growth and angiogenesis in preclinical models. Do not use with any active cancer diagnosis.

    Common Issues & Solutions

    No effect observed at injection site: SC bioavailability is very low: rapid NEP-mediated extracellular degradation means most peptide degrades before any systemic distribution. Inject as close to target wound tissue as possible. Distant SC injection (e.g., abdomen for a knee wound) is pharmacologically unsupported.

    Pain amplification at injection site: NK1R activation is inherently pro-nociceptive: this is expected pharmacology, not a side effect to suppress. Reduce dose or discontinue if pain is disproportionate to the wound being treated.

    Erythema and edema at injection site: Expected acute neurogenic inflammatory response via NK1R-mediated mast cell degranulation and vasodilation. Typically resolves within hours as peptide is enzymatically degraded. Persistent or worsening erythema beyond 24h warrants discontinuation.

    Reconstituted vial losing potency quickly: SP is an 11-AA peptide sensitive to oxidation and protease contamination. Aliquot into single-use volumes immediately after reconstitution. Do not store reconstituted solution >7 days at 4°C. Avoid repeated freeze-thaw cycles.

    Bronchoconstriction or wheezing after injection: NK1R is expressed on airway smooth muscle: this is a contraindication in practice. Discontinue immediately. Do not use in any subject with asthma, COPD, or reactive airway history.

    Ask AI about this page

    Ask AI for a second opinion on Substance P dosing and side effects

    Contraindications

    • Active asthma or bronchoconstriction disorders: Substance P can induce bronchoconstriction via NK1R on airway smooth muscle
    • Chronic inflammatory conditions (e.g., rheumatoid arthritis, IBD): may exacerbate inflammation
    • Pregnancy and breastfeeding: no safety data available
    • Known hypersensitivity to tachykinin peptides
    • Active malignancy: Substance P and NK1R signaling have been implicated in tumor growth and angiogenesis
    • Neuropsychiatric conditions including major depression and anxiety disorders: Substance P is elevated in these conditions and exogenous administration may worsen symptoms

    Drug Interactions

    • NK1 receptor antagonists (aprepitant, fosaprepitant, netupitant): directly block the target receptor, negating Substance P effects
    • Opioid analgesics: additive effects on pain pathways; Substance P modulates opioid receptor sensitivity
    • NSAIDs and corticosteroids: may partially counteract neurogenic inflammation induced by Substance P
    • ACE inhibitors: ACE degrades Substance P; inhibition may potentiate and prolong Substance P effects, contributing to ACE-inhibitor cough
    • Antihistamines: may blunt mast cell degranulation effects of Substance P
    • Immunosuppressants: Substance P promotes immune activation, potentially counteracting immunosuppressive therapy

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)Baseline before starting; repeat at week 2 if continuingCRP <10 mg/L; ESR within age/sex normal limits
    Spirometry / Peak expiratory flowBefore starting: contraindicated if obstructive pattern (FEV1/FVC <0.7) or any reactive airway historyNot listed
    Local wound site assessment (photography + measurement)At each injection session and weeklyNot listed
    C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)

    SP is pro-inflammatory via NK1R. Systemic inflammatory markers elevation signals excessive or unintended systemic inflammatory response.

    Spirometry / Peak expiratory flow

    SP induces bronchoconstriction via NK1R on airway smooth muscle. This is a hard contraindication in asthma/COPD.

    Local wound site assessment (photography + measurement)

    Primary endpoint for any wound healing application. Distinguishes therapeutic wound healing response from pathological neurogenic inflammation. Documented photo record allows objective assessment of wound closure rate.

    Substance P Before and After

    Minutes

    Rapid NK1 receptor activation. Immediate vasodilation and plasma extravasation at injection site. Mast cell degranulation and histamine release may occur. Effects are transient due to ~1-2 minute half-life.

    Hours 1-6

    Neurogenic inflammatory response peaks. Localized edema, erythema, and immune cell recruitment observed. Fibroblast and keratinocyte stimulation begins at the tissue level.

    Days 1-3

    With repeated dosing, measurable increases in local immune cell infiltration and early wound healing markers. Bone marrow stem cell mobilization begins in animal models.

    Weeks 1-2

    Accelerated wound closure and re-epithelialization observed in corneal and dermal wound models. Angiogenesis markers (VEGF) elevated. Collagen deposition increased at wound sites.

    Weeks 3-4

    Maximal tissue repair effects in research models. Continued immune modulation. Evaluate inflammatory markers to ensure no chronic inflammation. Consider cycling off.

    What to Expect

    Minutes 0 to 30 post-injection: NK1R activates within seconds at the injection site. Mast cells degranulate, releasing histamine. Local vasodilation and plasma extravasation begin immediately. Pain amplification at the site is expected. These effects are transient because NEP degrades SP in tissue within 1 to 2 minutes. Systemic exposure from subcutaneous injection is minimal.

    Hours 1 to 6: Neurogenic inflammation peaks at the injection site. Neutrophils and macrophages begin arriving. Fibroblast and keratinocyte stimulation starts through downstream NK1R signaling. Local edema and erythema continue. Pain at the injection site persists.

    Days 1 to 3: With repeated daily dosing, local immune cell infiltration becomes measurable. Early wound healing markers begin to rise in animal models. Kim's 2009 data [1] showed bone marrow stem cell mobilization starting within this window in mice and rabbits. No human data confirms this timeline.

    Weeks 1 to 2: Preclinical wound models show accelerated wound closure and re-epithelialization. VEGF levels climb at wound sites. Collagen deposition increases. Khalifa's 2024 work [2] confirmed SP restores asymmetric stem cell divisions in denervated skin during this window. All of this is animal model data.

    Weeks 3 to 4: Maximum tissue repair effects observed in research models. Inflammatory marker monitoring becomes critical. CRP and ESR should be checked. Chronic neurogenic inflammation risk increases with continued use. Standard research practice calls for cycling off at week 4 with an equal 4-week off period before any rechallenge.

    Detailed Timeline: Science vs Community

    Minutes 0–30 post-injection
    Science

    Rapid NK1R binding within seconds. Mast cell degranulation, histamine release, vasodilation, plasma extravasation at injection site. Effects are transient: tissue half-life is ~1-2 min (extracellular NEP-mediated). Plasma half-life is also short (1.6 min during IV infusion in healthy subjects, PMID 2425412), and systemic exposure from SC is minimal.

    Community

    No community data: no self-administration reports exist.

    Hours 1–6
    Science

    Peak neurogenic inflammatory response at injection site. Neutrophil and macrophage recruitment begins. Fibroblast and keratinocyte stimulation initiates via NK1R and downstream signaling.

    Community

    No community data.

    Days 1–3
    Science

    With repeated dosing: measurable increases in local immune cell infiltration, early wound healing marker elevation. Bone marrow stem cell mobilization begins in animal models (Kim 2009 PMID 19270709).

    Community

    No community data.

    Weeks 1–2
    Science

    Accelerated wound closure and re-epithelialization in corneal and dermal animal wound models. Elevated VEGF, increased angiogenesis. Collagen deposition increased at wound sites. Khalifa 2024 (PMID 38301639): SP restores asymmetric stem cell divisions in denervated skin.

    Community

    No community data.

    Weeks 3–4
    Science

    Maximal tissue repair effects observed in animal models. Extended use risks chronic neurogenic inflammation. Inflammatory marker monitoring recommended. Cycling off standard practice in research protocols.

    Community

    No community data.

    Pharmacokinetics

    Half-Life
    2min
    Bioavailability
    IV: 100%; SC: very low due to rapid local enzymatic degradation
    Tmax
    <1 minute (IV); ~5-10 minutes (SC, local tissue levels)
    Data Confidence
    high

    Source: Substance P is rapidly degraded by neutral endopeptidase (NEP/CD10) and angiotensin-converting enzyme (ACE). Plasma half-life of exogenous substance P was 1.6 minutes during IV infusion in 6 healthy subjects (PMID 2425412)

    Pharmacokinetics: Active Dose Over Time

    t½ = ~1-2 minutes (rapid enzymatic degradation)

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    11
    Sequence
    RPKPQQFFGLM
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers

    Who Should Consider Substance P

    • Researchers studying nociception and pain pathways
    • Scientists investigating neurogenic inflammation mechanisms
    • Clinicians researching wound healing and tissue regeneration
    • Researchers exploring immune-neural crosstalk
    • Investigators studying corneal wound repair
    • Scientists developing NK1 receptor antagonist therapies (e.g., aprepitant)

    Related Peptides

    What Changed for Substance P

    No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

    Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

    References

    1. [1]A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells (Nat Med 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Neuropeptide substance P alters stem cell fate to aid wound healing and promote epidermal stratification through asymmetric stem cell divisions (Stem Cells 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
    3. [3]Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype (Am J Pathol 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]The role of substance P in inflammatory disease (J Cell Physiol 2004) (opens in a new tab)PubMed (opens in a new tab)Review
    5. [5]Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man (Schaffalitzky de Muckadell et al., Scand J Gastroenterol 1986) (opens in a new tab)PubMed (opens in a new tab)PubMed

    Related Tools

    Storage & Stability

    Before Reconstitution
    Store at -20°C for long-term stability, up to 2 years. Stable at 4°C for several months.
    After Reconstitution
    Refrigerate at 2-8°C, use within 7 days. Aliquot to avoid freeze-thaw cycles.
    Temperature
    -20°C (long-term) or 2-8°C (short-term)

    Frequently Asked Questions

    It's genuinely dual-role. The same NK1R activation that amplifies pain also stimulates fibroblasts, blood vessel formation, and bone marrow stem cell mobilization. Short-term, it's pro-inflammatory (which is necessary to kick off healing). Over days to weeks, it's pro-regenerative. The peptide makes you feel pain while helping you heal.

    Great question, and honestly, it's the core pharmacological limitation. With degradation enzymes abundant in tissue fluid, a SubQ dose is mostly destroyed locally before reaching systemic circulation. Any effect from SubQ would be primarily local, near the injection site. Clinical research uses continuous IV infusion for systemic effects or topical application for corneal wound healing. Daily SubQ for systemic benefit has no published support.

    They're pharmacological opposites. Substance P activates the NK1 receptor (transmitting pain, promoting healing). Aprepitant (Emend) blocks the NK1 receptor (preventing nausea in chemo patients). Using both together would cancel each other out.

    No human clinical trials exist for systemic Substance P administration for wound healing. The evidence is entirely preclinical (mouse, rat, rabbit models). There's indirect clinical evidence from Substance P deficiency contributing to poor wound healing in diabetic neuropathy. Topical eye drops with SP fragments have been studied in small corneal healing trials, but systemic use hasn't reached human testing.

    Yes, measurably. ACE is one of the main enzymes that breaks down Substance P. When ACE inhibitors like lisinopril block this enzyme, both bradykinin and Substance P accumulate in the respiratory tract. That accumulation is what causes the dry cough affecting 10-15% of ACE inhibitor users, particularly in Asian populations.